On the surface, 2024 appeared to be another banner year for equity markets, but beneath the hood, the story was categorically ...

A recent analysis from a randomized clinical trial conducted by researchers at the Dana-Farber Brigham Cancer Center ...

A data analysis from a randomized clinical trial for stage 3 colon cancer patients found that patients with evidence of residual cancer in their blood after surgery to remove the cancer, may benefit ...

A research team revealed that insulin-like growth factor-binding protein 6 (IGFBP6) serves as a potential therapeutic target ...

Natera has reported the latest data from the Phase III CALGB (Alliance)/SWOG 80702 study, indicating that Signatera, a ...

A data analysis from a randomized clinical trial for stage 3 colon cancer patients by investigators at Dana-Farber Brigham ...

Although ctDNA positivity generally meant worse disease-free survival in stage 3 resected colon cancer, patients with ctDNA ...

Reinsurance Group of America, Incorporated (NYSE:RGA), with a substantial market capitalization of $14.78 billion, has been ...

A research team led by Prof. WENG Jianping from the University of Science and Technology of China (USTC) of the Chinese ...

An updated exploratory analysis of the clinically important subgroup of patients with residual invasive disease of 1 cm or less and negative axillary nodes (328 patients) showed a hazard ratio for ...

Reinsurance Group of America (RGA), Incorporated, a provider of life and health reinsurance, has made a strategic investment in and anchor commitment to PACT Capital LLC, an independent investment ...